反応式
[Cl:1][C:2]1[N:7]=[CH:6][C:5]2[CH:8]=[N:9][NH:10][C:4]=2[CH:3]=1.Br[C:12]1[N:17]=[C:16]([N:18]2[CH2:24][CH2:23][CH2:22][N:21]([C:25]([O:27][C:28]([CH3:31])([CH3:30])[CH3:29])=[O:26])[CH2:20][CH2:19]2)[CH:15]=[N:14][CH:13]=1.CNCCNC.C(=O)([O-])[O-].[K+].[K+]>O1CCOCC1>[Cl:1][C:2]1[N:7]=[CH:6][C:5]2[CH:8]=[N:9][N:10]([C:12]3[N:17]=[C:16]([N:18]4[CH2:24][CH2:23][CH2:22][N:21]([C:25]([O:27][C:28]([CH3:31])([CH3:30])[CH3:29])=[O:26])[CH2:20][CH2:19]4)[CH:15]=[N:14][CH:13]=3)[C:4]=2[CH:3]=1参加物
6
反応物 4
生成物 1
試薬・触媒・溶媒 1
反応条件
- 温度
- 110 °C
実験手順
A mixture of 6-chloro-1H-pyrazolo[4,3-c]pyridine (2.0 mmol; 307 mg), tert-butyl 4-(6-bromopyrazin-2-yl)-1,4-diazepane-1-carboxylate (2.199 mmol; 785.5 mg), N,N′-Dimethylethylenediamine (4.0 mmol; 352.4 mg; 0.398 mL), cuprous iodide (2.0 mmol; 380.72 mg), and potassium carbonate (2.1990 mmol; 307 mg) in 1,4-Dioxane (15 mL) was purged with Argon, then sealed and stirred at 110° C. overnight. The mixture was cooled to room temperature, then filtered through Celite. The filtrate was concentrated; the residue was purified on silica eluted with 0 to 100% EtOAc in Heptane to afford tert-butyl 4-[6-(6-chloropyrazolo[4,3-c]pyridin-1-yl)pyrazin-2-yl]-1,4-diazepane-1-carboxylate as an off-white solid (217.2 mg, 25%). MS (ESI) m/z: δ 430 [M+H]+
後処理
- customwas purged with Argon
- customsealed
- temperatureThe mixture was cooled to room temperature
- filtrationfiltered through Celite
- concentrationThe filtrate was concentrated
- customthe residue was purified on silica
- washeluted with 0 to 100% EtOAc in Heptane
出典と根拠
- ORDレコード
- ord-70c68bcf541c473dbdd1b6a191abd611
- 出典データセット
- uspto-grants-2016_09
- 特許番号
- US09434725B2
関連ノート
読み込み中…